Trial Profile
A Phase 2 Study of GTX-SRS: Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery for Borderline Resectable Pancreatic Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 26 May 2010 Actual patient number (2) added as reported by ClinicalTrials.gov.
- 26 May 2010 Planned end date changed from 1 Mar 2012 to 1 Mar 2010 as reported by ClinicalTrials.gov.
- 26 May 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.